The Problem: Governance That Slows Everything Down
In pharma, governance often becomes synonymous with bureaucracy — layers of approval committees that slow decisions without adding value. Steering committees review slide decks but defer all decisions. Program boards re-discuss issues already resolved at workstream level. Compliance reviews occur at the end rather than being integrated throughout. The result: programs grind to a halt under the weight of their own governance.
The Solution: Decision-Enabling Governance
Effective program governance clarifies decision rights, accelerates escalation, and ensures the right people make the right decisions at the right level. It is the opposite of bureaucracy.
The Approach: Tiered, Disciplined, Decision-Focused
- Tiered decision authority: Workstream leads handle tactical decisions, program board handles cross-workstream trade-offs, steering committee handles strategic direction
- Clear escalation triggers: Quantified thresholds for scope, timeline, budget, and compliance deviations
- Decision velocity: Maximum turnaround times at each governance tier
- Standing agenda discipline: Structured decision agendas, not status updates
- Quality and compliance integration: Regulatory representatives embedded in governance, not consulted ad hoc
How ANG Associates Can Help
ANG Associates designs and implements program governance frameworks for pharma enterprises. We've seen what works and what doesn't across multiple organizations — and we bring battle-tested governance templates, RACI structures, and escalation protocols that can be adapted to your organizational context. We help standing up governance that enables speed while maintaining the accountability and compliance rigor that pharma demands.